SLC5A2 and type 2 diabetes mellitus: In addition, a recent clinical study reported that 12-month treatment of T2DM patients with glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors results in a significantly thicker endothelial glycocalyx than that seen in patients treated with insulin [84].